<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo>/myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPNs) are a group of myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in which abnormal activation of the Ras signaling pathway is commonly observed </plain></SENT>
<SENT sid="1" pm="."><plain>The PI3K/Akt pathway is a known target of Ras; however, activation of the PI3K/Akt pathway has been shown to lead to <z:e sem="disease" ids="C0007621" disease_type="Neoplastic Process" abbrv="">neoplastic transformation</z:e> of not only myeloid but also lymphoid cells, suggesting that pathways other than the PI3K/Akt pathway should play a central role in pathogenesis of Ras-mediated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN </plain></SENT>
<SENT sid="2" pm="."><plain>The MEK/ERK pathway is another downstream target of Ras, which is involved in regulation of cell survival and proliferation </plain></SENT>
<SENT sid="3" pm="."><plain>However, the role of the MEK/ERK pathway in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN remains unclear </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we show that introduction of a constitutively activated form of MEK into hematopoietic stem cells (<z:chebi fb="15" ids="50443">HSCs</z:chebi>) causes hematopoietic <z:hpo ids='HP_0002664'>neoplasms</z:hpo> that are limited to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPNs, despite the multipotent differentiation potential of <z:chebi fb="15" ids="50443">HSCs</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Active MEK-mediated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPNs are lethal, but are not considered a frank <z:hpo ids='HP_0001909'>leukemia</z:hpo> because it cannot be transplanted into na√Øve animals </plain></SENT>
<SENT sid="6" pm="."><plain>However, transplantation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPNs co-expressing active MEK and an anti-apoptotic molecule, Bcl-2, results in T-cell <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e>), suggesting that longevity of cells may impact transplantability and alter disease phenotype </plain></SENT>
<SENT sid="7" pm="."><plain>Our results clearly demonstrate the proto-oncogenic property of the MEK/ERK pathway in hematopoietic cells, which manifest in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN development </plain></SENT>
</text></document>